为方便大家, 我找了个软件翻译了全文(部分手工矫正了) $沃森生物(SZ300142)$
摘要:
Homologous and heterologous booster with COVID-19 mRNA vaccines represent the most effective strategy to prevent the ongoing Omicron pandemic. The additional protection from these prototype SARS-CoV-2 S-targeting vaccine was attributed to the increased RBD-specific memory B cells with expanded potency and breadth. Herein, we show the safety and immunogenicity of heterologous boosting with the RBD-targeting mRNA vaccine AWcorna (also term ARCoV) in Chinese adults who have received two doses inactivated vaccine. The superiority over inactivated vaccine in neutralization antibodies, as well as the safety profile, support the use of AWcorna as heterologous booster in China.
COVID-19 mRNA 疫苗的同源和异源加强剂是预防正在进行的 Omicron 大流行的最有效策略。这些原型 SARS-CoV-2 S 靶向疫苗的额外保护归因于 RBD 特异性记忆 B 细胞的增加，具有扩展的效力和广度。在此，我们展示了在接受过两剂灭活疫苗的中国成年人中使用 RBD 靶向 mRNA 疫苗 AWcorna（也称为 ARCoV）进行异源加强免疫的安全性和免疫原性。在中和抗体方面以及安全性优于灭活疫苗，支持在中国使用 AWcorna 作为异源加强针接种。
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2100053701
Funding Statement
This work was supported in part by grant from the National Key Research and Development Program of China (2021YFC2302400) and the National Science Foundation of China (82151222). C.-F.Q. was supported by the National Science Fund for Distinguished Young Scholars (81925025), the Innovative Research Group (81621005) from the National Science Foundation of China and the Innovation Fund for Medical Sciences (2019-I2M-5-049) from the Chinese Academy of Medical Science.
竞争利益声明
作者已声明没有竞争利益。
临床试验
ChiCTR2100053701
资金声明
这项工作得到了国家重点研发计划 (2021YFC2302400) 和国家自然科学基金 (82151222) 的部分资助。 C.-F.Q.国家杰出青年科学基金（81925025）、国家自然科学基金创新研究组（81621005）和中国科学院医学科学创新基金（2019-I2M-5-049）资助医药科学。
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Committee of the Center for Disease Control and Prevention of Yunnan province gave ethical approve for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
作者声明
我确认已遵循所有相关的道德准则，并且已获得任何必要的 IRB 和/或道德委员会批准:
是的
为所述研究提供批准或豁免的 IRB/监督机构的详细信息如下：
云南省疾病预防控制中心研究伦理委员会对该工作给予了伦理批准。
我确认已获得所有必要的患者/参与者同意并已存档适当的机构表格，并且包含的任何患者/参与者/样本标识符都不为研究之外的任何人（例如，医院工作人员、患者或参与者本身）所知组，因此不能用于识别个人。
是的
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
我了解所有临床试验和任何其他前瞻性干预研究都必须在 ICMJE 批准的注册机构注册，例如 ClinicalTrials.gov。
我确认手稿中报告的任何此类研究都已注册并提供了试验注册 ID（注意：如果发布回顾性注册的前瞻性研究，请在试验 ID 字段中提供声明，解释为什么该研究未提前注册） .
是的
我已遵循所有适当的研究报告指南，并上传了相关的 EQUATOR 网络研究报告清单和其他相关材料作为补充文件（如果适用）。
是的